Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

INDUSTRY 3NIH 2OTHER 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Breast 2Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Squamous Cell 2Neoplasm Metastasis 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × advexin × Head & Neck × Clear all
NCT02842125 2020-06-02

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

MultiVir, Inc.

Phase 1/2 Terminated
4 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis

NCT00041613 2008-04-01

Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate

Introgen Therapeutics

Phase 3 Unknown
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT00041626 2007-09-11

Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone

Introgen Therapeutics

Phase 3 Unknown
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡